A61K9/1611

IMMEDIATE RELEASE FORMULATIONS OF CANNABINOIDS
20220378703 · 2022-12-01 · ·

Compositions for the immediate release of one or more cannabinoids, in which the compositions comprise a population of particles. Each particle may comprise the one or more cannabinoids and one or more intra-granule excipients. Alternatively, each particle may comprise the one or more cannabinoids and a porous bead core. The composition may be prepared by a method that involves combining the one or more cannabinoids with the one or more intra-granule excipients, and then granulating the combination, such as through fluid bed granulation, shear-induced wet granulation, or spray granulation. The composition may also be prepared by a method that involves mixing the one or more cannabinoids with a population of porous bead cores.

MEDICAL COUNTER MEASURES INCLUDING DRY POWDER FORMULATIONS AND ASSOCIATED METHODS
20230191047 · 2023-06-22 · ·

Provided herein are dry powder formulations comprising at least one active pharmaceutical ingredient suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including respiratory conditions, hemodynamic collapse, seizures, migraines, and other conditions.

ION IMPLANTATION OF MAGNETIC ELEMENTS INTO NANODIAMOND PARTICLES TO FORM COMPOSITION FOR MEDICAL USAGE
20170354601 · 2017-12-14 ·

A composition for medical usage and method of preparing the same are provided. The composition comprises: at least one magnetic nanoparticle including a nanodiamond particle and at least one magnetic element, wherein the at least one magnetic element is embedded into the at least one nanodiamond particle by using an ion implantation system. The nanodimond particle can be synthesized with different components which can help medical effects of the composition.

Dry formulations of vaccines that are room temperature stable
09839613 · 2017-12-12 · ·

The present invention discloses dry formulations of room temperature stable vaccines that comprise a live attenuated virus, a sugar stabilizer, and an amino acid stabilizer. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.

Starch-free soft chew for veterinary applications

The present invention relates to a starch-free soft chew formulation for oral delivery of at least one active ingredient to an animal, and a starch-free soft chew containing the formulation and at least one active ingredient. The starch-free soft chew includes one or more active ingredients and excipients, such as a bulking agent, a flavoring agent, a humectant, a preservative, an antioxidant, and a lubricant, but no added water. In addition, the invention relates to a composition of starch-free, non-water excipients for use in the final dosage form of a soft chew for oral administration of at least one active ingredient to an animal. Also provided are processes for making the starch-free soft chew formulation and the starch-free soft chew.

CONTROLLED RELEASE OF ACTIVE SUBSTANCES
20170348223 · 2017-12-07 ·

A water-insoluble composition, solid in appearance at a temperature of less than or equal to 20° C., comprising, for 100% of the mass of same:—X1% by mass of at least one lipophilic surfactant having a value HLB, H1, greater than or equal to 1 and less than 10;—X2% by mass of at least one hydrophilic surfactant having a value HLB, H2, greater than or equal to 10 and less than or equal to 20; characterised by the fact that the HLB of same=X1.H1+X2.H2, X1 and X2 varying from 2 to 60, and characterised in that it is free of acrylic polymer and/or of acetate succinate.

POROUS PARTICLES
20170348302 · 2017-12-07 ·

Processes for preparing porous particles are disclosed, in which the resulting particles release an encapsulated active ingredient more readily in aqueous media than they do in alcoholic media. Also described are the particles themselves, as well as tamperproof, abuse-deterrent, dosage forms comprising the porous particles. The release characteristics of the porous particles make them useful for overcoming drug-abuse techniques, such as dose-dumping in alcoholic media.

SOLID COMPOSITIONS OF TRIGLYCERIDES AND USES THEREOF
20230181513 · 2023-06-15 ·

The present invention includes solid compositions of triglycerides with one or more fatty acids, such as triheptanoin and glycerol phenylbutyrate, and therapeutic use thereof. The solid compositions can be prepared by spray-drying or other processes.

INJECTABLE NEUROSTEROID FORMULATIONS CONTAINING NANOPARTICLES
20230181600 · 2023-06-15 ·

The disclosure provides an injectable neurosteroid nanoparticle formulation comprising nanoparticles having a D50 of less than 2000 nm the nanoparticles comprising a neurosteroid of Formula I,

##STR00001##

where the variables R.sup.1-R.sup.9 and X are defined herein and at least one surface stabilizer. The surface stabilizer can be a polymeric surface stabilizer such as hydroxyethyl starch, dextran, or povidone. The injectable neurosteroid nanoparticle formulation can be an intravenous formulation. The disclosure also provides a lyophilized powder of the injectable neurosteroid nanoparticle formulation that can be reconstituted in an aqueous solution prior to administration. The disclosure provides injectable neurosteroid nanoparticle formulations and dry powders of such formulations that have been sterilized by ebeam irradiation. The disclosure provides a method of treating a patient having a seizure disorder, stroke, or traumatic brain injury, comprising administering an effective amount of the injectable neurosteroid nanoparticle formulation. The disclosure also provides combination methods in which the injectable neurosteroid nanoparticle formulation is a first active agent that is administered in combination with at least one additional active agent.

PROCESS OF MAKING IVABRADINE HYDROCHLORIDE DRUG PRODUCT

A new process for making ivabradine hydrochloride drug product reduces the amount of amorphous ivabradine hydrochloride in the drug product.

##STR00001##